NCT00768339: A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas |
|
|
| Terminated | 1/2 | 25 | US, Canada | AEG35156 antisense IV infusion, XIAP antisense | Aegera Therapeutics, The Leukemia and Lymphoma Society | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell | 06/11 | 09/11 | | |
